FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128088552> ?p ?o ?g. }

• W3128088552 abstract "Estrogen signaling is essential for normal uterine function and has been shown to play critical roles in the development of endometrial cancer. Mutations in the ligand binding domain (LBD) of estrogen receptor alpha (ER) have been identified in primary endometrial cancer and hormone therapy resistant breast cancer. In endometrial cancer, ER mutations are associated with worse outcomes and obesity independent disease. However, additional molecular and phenotypic characterizations of these mutations are needed in the context of endometrial cancer. Utilizing a CRISPR/Cas9 tagging strategy to model the more common Y537S and D538G LBD mutations while epitope tagging ER’s endogenous locus in Ishikawa cells, we studied the regulatory and phenotypic consequences of mutant ER in endometrial cancer and have identified potential targeted therapies for the treatment of this disease. RNA sequencing (RNA-seq) experiments uncovered expression changes caused by ER mutations, including both estradiol-regulated genes and mutation-specific, estradiol-independent genes. We found mutation-specific changes in gene expression were not recapitulated with prolonged estrogen exposure in wildtype cells, suggesting the mutant ER transcriptome is distinct from constitutive ER activity. The unique mutant ER expression program was related to phenotypic changes in ER mutant endometrial cancer cells, including increased proliferation specifically in vivo and increased migration in vitro relative to wildtype cells, consistent with more aggressive endometrial tumors. Based on the transcriptional and phenotypic alterations caused by mutant ER, we explored gene regulation based drugs for the potential treatment of mutant ER endometrial tumors. We found that two small molecules, cyclin dependent kinase 9 (CDK9) inhibitor Alvocidib and steroid receptor coactivator 3 (SRC-3) inhibitor SI-2, decreased mutant ER’s ability to promote proliferation and migration. In conclusion, mutant ER confers estrogen-independent activity while causing additional regulatory changes in endometrial cancer cells. This activity has led us to identify two drugs that show efficacy in treating mutant ER endometrial cancer cells, however further study is needed to ascertain whether they can be utilized as novel therapeutic targets in this disease.Citation Format: Zannel Blanchard, Jeffery M. Vahrenkamp, Spencer Arnesen, Kristofer C. Berrett, Jason Gertz. Characterization of molecular, phenotypic, and drug sensitivity changes due to estrogen receptor alpha mutations in endometrial cancer [abstract]. In: Proceedings of the AACR Virtual Special Conference: Endometrial Cancer: New Biology Driving Research and Treatment; 2020 Nov 9-10. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(3_Suppl):Abstract nr PO012." @default.
• W3128088552 created "2021-02-15" @default.
• W3128088552 creator A5010761495 @default.
• W3128088552 creator A5013403430 @default.
• W3128088552 creator A5034085129 @default.
• W3128088552 creator A5038042793 @default.
• W3128088552 creator A5071505980 @default.
• W3128088552 date "2021-02-01" @default.
• W3128088552 modified "2023-09-27" @default.
• W3128088552 title "Abstract PO012: Characterization of molecular, phenotypic, and drug sensitivity changes due to estrogen receptor alpha mutations in endometrial cancer" @default.
• W3128088552 doi "https://doi.org/10.1158/1557-3265.endomet20-po012" @default.
• W3128088552 hasPublicationYear "2021" @default.
• W3128088552 type Work @default.
• W3128088552 sameAs 3128088552 @default.
• W3128088552 citedByCount "0" @default.
• W3128088552 crossrefType "proceedings-article" @default.
• W3128088552 hasAuthorship W3128088552A5010761495 @default.
• W3128088552 hasAuthorship W3128088552A5013403430 @default.
• W3128088552 hasAuthorship W3128088552A5034085129 @default.
• W3128088552 hasAuthorship W3128088552A5038042793 @default.
• W3128088552 hasAuthorship W3128088552A5071505980 @default.
• W3128088552 hasConcept C104317684 @default.
• W3128088552 hasConcept C121608353 @default.
• W3128088552 hasConcept C143065580 @default.
• W3128088552 hasConcept C172313692 @default.
• W3128088552 hasConcept C2777088508 @default.
• W3128088552 hasConcept C502942594 @default.
• W3128088552 hasConcept C530470458 @default.
• W3128088552 hasConcept C54355233 @default.
• W3128088552 hasConcept C84606932 @default.
• W3128088552 hasConcept C86803240 @default.
• W3128088552 hasConceptScore W3128088552C104317684 @default.
• W3128088552 hasConceptScore W3128088552C121608353 @default.
• W3128088552 hasConceptScore W3128088552C143065580 @default.
• W3128088552 hasConceptScore W3128088552C172313692 @default.
• W3128088552 hasConceptScore W3128088552C2777088508 @default.
• W3128088552 hasConceptScore W3128088552C502942594 @default.
• W3128088552 hasConceptScore W3128088552C530470458 @default.
• W3128088552 hasConceptScore W3128088552C54355233 @default.
• W3128088552 hasConceptScore W3128088552C84606932 @default.
• W3128088552 hasConceptScore W3128088552C86803240 @default.
• W3128088552 hasLocation W31280885521 @default.
• W3128088552 hasOpenAccess W3128088552 @default.
• W3128088552 hasPrimaryLocation W31280885521 @default.
• W3128088552 hasRelatedWork W1927362057 @default.
• W3128088552 hasRelatedWork W1975559054 @default.
• W3128088552 hasRelatedWork W1985664755 @default.
• W3128088552 hasRelatedWork W2351080533 @default.
• W3128088552 hasRelatedWork W2606688994 @default.
• W3128088552 hasRelatedWork W2883582020 @default.
• W3128088552 hasRelatedWork W2965634873 @default.
• W3128088552 hasRelatedWork W3015567060 @default.
• W3128088552 hasRelatedWork W3102914996 @default.
• W3128088552 hasRelatedWork W4361823172 @default.
• W3128088552 isParatext "false" @default.
• W3128088552 isRetracted "false" @default.
• W3128088552 magId "3128088552" @default.
• W3128088552 workType "article" @default.